Savara Announces Patient Journey Map for People Living with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Accepted for Poster Presentation at the CHEST 2024 Annual Meeting
Savara, a clinical-stage biopharmaceutical company focused on rare respiratory diseases, announced the acceptance of an abstract for poster presentation at the CHEST 2024 Annual Meeting, scheduled for October 6-9 in Boston. The abstract, titled “A Patient Journey Map for People Living with Autoimmune Pulmonary Alveolar Proteinosis (aPAP),” will be featured in the Diffuse Lung Disease Abstracts Posters (D) session on October 8, 2024, from 1:45 to 2:30pm EDT. Additionally, Savara is sponsoring an Industry Symposium at the meeting, titled “Pulmonary Alveolar Proteinosis: Pathophysiology, Diagnosis, and Management,” which will take place on October 8, 2024, from 2:00 to 2:45pm EDT at the CHEST Learning Theater. The symposium will be led by Dr. Ali Ataya, Associate Professor of Medicine at the University of Florida, Division of Pulmonary and Critical Care Medicine.
Savara, un'azienda biofarmaceutica in fase clinica focalizzata su malattie respiratorie rare, ha annunciato l'accettazione di un abstract per una presentazione poster al CHEST 2024 Annual Meeting, in programma dal 6 al 9 ottobre a Boston. L'abstract, intitolato “Una Mappa del Percorso del Paziente per le Persone che Vivono con la Proteinosi Alveolare Polmonare Autoimmune (aPAP),” sarà presentato nella sessione Diffuse Lung Disease Abstracts Posters (D) l'8 ottobre 2024, dalle 13:45 alle 14:30 EDT. Inoltre, Savara sta sponsorizzando un Simposio Industriale durante l'incontro, intitolato “Proteinosi Alveolare Polmonare: Fisiopatologia, Diagnosi e Gestione,” che si terrà l'8 ottobre 2024, dalle 14:00 alle 14:45 EDT presso il CHEST Learning Theater. Il simposio sarà condotto dal Dott. Ali Ataya, Professore Associato di Medicina presso l'Università della Florida, Divisione di Medicina Polmonare e Terapia Intensiva.
Savara, una empresa biofarmacéutica en etapa clínica centrada en enfermedades respiratorias raras, anunció la aceptación de un resumen para una presentación de póster en el CHEST 2024 Annual Meeting, programado del 6 al 9 de octubre en Boston. El resumen, titulado “Un Mapa del Viaje del Paciente para Personas que Viven con Proteinosis Alveolar Pulmonar Autoinmune (aPAP),” se presentará en la sesión de Pósters de Resúmenes de Enfermedades Pulmonares Difusas (D) el 8 de octubre de 2024, de 1:45 a 2:30 p.m. EDT. Además, Savara patrocinará un Simpósio de la Industria en la reunión, titulado “Proteinosis Alveolar Pulmonar: Fisiopatología, Diagnóstico y Manejo,” que tendrá lugar el 8 de octubre de 2024, de 2:00 a 2:45 p.m. EDT en el CHEST Learning Theater. El simposio será dirigido por el Dr. Ali Ataya, Profesor Asociado de Medicina en la Universidad de Florida, División de Medicina Pulmonar y Cuidados Críticos.
사바라는 희귀 호흡기 질환에 집중하는 임상 단계의 생명공학 회사로, CHEST 2024 연례 회의에서 포스터 발표를 위한 초록이 수락되었다고 발표했습니다. 이 회의는 10월 6일부터 9일까지 보스턴에서 개최됩니다. 초록의 제목은 “자가면역 폐포 단백증(aPAP) 환자를 위한 여정 지도”이며, 2024년 10월 8일 오후 1시 45분부터 2시 30분 EDT까지 진행되는 확산 폐 질환 초록 포스터(D) 세션에서 소개될 예정입니다. 또한, 사바라는 회의에서 “폐포 단백증: 병리생리학, 진단 및 관리”라는 제목의 산업 심포지엄을 후원할 예정이며, 이는 2024년 10월 8일 오후 2시부터 2시 45분 EDT까지 CHEST 학습 극장에서 열릴 것입니다. 이 심포지엄은 플로리다 대학교 의과대학의 알리 아타야 박사가 이끌 것입니다.
Savara, une entreprise bio-pharmaceutique en phase clinique spécialisée dans les maladies respiratoires rares, a annoncé l'acceptation d'un résumé pour une présentation d'affiche lors du CHEST 2024 Annual Meeting, prévu du 6 au 9 octobre à Boston. Le résumé, intitulé “Une Carte du Parcours Patient pour les Personnes Vivant avec une Protéinose Alvéolaire Pulmonaire Auto-immune (aPAP),” sera présenté lors de la session des Résumés sur les Maladies Pulmonaires Diffuses (D) le 8 octobre 2024, de 13h45 à 14h30 EDT. De plus, Savara parrainera un Symposium de l'Industrie lors de la réunion, intitulé “Protéinose Alvéolaire Pulmonaire : Physiopathologie, Diagnostic et Gestion,” qui se tiendra le 8 octobre 2024, de 14h00 à 14h45 EDT au CHEST Learning Theater. Le symposium sera dirigé par le Dr Ali Ataya, professeur associé de médecine à l'Université de Floride, Division de Médecine Pulmonaire et de Soins Intensifs.
Savara, ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf seltene Atemwegserkrankungen spezialisiert, hat die Annahme eines Abstracts für eine Posterpräsentation auf dem CHEST 2024 Annual Meeting bekannt gegeben, das vom 6. bis 9. Oktober in Boston stattfinden wird. Das Abstract mit dem Titel “Eine Patientenreise-Karte für Menschen mit Autoimmuner Pulmonaler Alveolären Proteinosis (aPAP)” wird am 8. Oktober 2024 von 13:45 bis 14:30 Uhr EDT in der Sitzung Diffuse Lung Disease Abstracts Posters (D) vorgestellt. Darüber hinaus sponsert Savara ein Industrie-Symposium auf dem Meeting mit dem Titel “Pulmonale Alveolare Proteinosis: Pathophysiologie, Diagnostik und Management,” das am 8. Oktober 2024 von 14:00 bis 14:45 Uhr EDT im CHEST Learning Theater stattfinden wird. Das Symposium wird von Dr. Ali Ataya, außerordentlicher Professor für Medizin an der Universität von Florida, Abteilung für Lungen- und Intensivmedizin, geleitet.
- Savara's abstract acceptance at CHEST 2024 highlights its focus on rare respiratory diseases.
- Sponsoring an Industry Symposium increases Savara's visibility in the medical community.
- None.
Company-Sponsored Industry Symposium to be Held at the CHEST 2024 Annual Meeting
Accepted Abstract
Title: “A Patient Journey Map for People Living with Autoimmune Pulmonary Alveolar Proteinosis (aPAP)”
Poster Session: Diffuse Lung Disease Abstracts Posters (D)
Date and Time: October 8, 2024, 1:45 - 2:30pm EDT
Company-Sponsored Symposium
Title: “Pulmonary Alveolar Proteinosis: Pathophysiology, Diagnosis, and Management”
Location: CHEST Learning Theater
Date and Time: October 8, 2024, 2:00 - 2:45pm EDT
Speaker: Ali Ataya, M.D., Associate Professor of Medicine, University of
About aPAP
Autoimmune PAP is a rare lung disease characterized by the abnormal build-up of surfactant in the alveoli (or air sacs) of the lungs. Surfactant consists of proteins and lipids and is an important physiological substance that lines the alveoli to prevent them from collapsing. In a healthy lung, excess surfactant is cleared and digested by immune cells called alveolar macrophages. Alveolar macrophages need to be stimulated by granulocyte-macrophage colony-stimulating factor (GM-CSF) to function properly in clearing surfactant, but in autoimmune PAP, GM-CSF is neutralized by antibodies against GM-CSF, rendering macrophages unable to adequately clear surfactant. As a result, an excess of surfactant accumulates in the alveoli, causing impaired gas exchange, resulting in clinical symptoms of shortness of breath, often with cough and frequent fatigue. Patients may also experience episodes of fever, chest pain, or coughing up blood, especially if secondary lung infection develops. In the long-term, the disease can lead to serious complications, including lung fibrosis and the need for a lung transplant.
About Savara
Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim inhalation solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com. (X, formerly known as Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).
View source version on businesswire.com: https://www.businesswire.com/news/home/20241001381874/en/
Savara Inc. IR & PR
Anne Erickson (anne.erickson@savarapharma.com)
(512) 851-1366
Source: Savara Inc.
FAQ
What is the date and time for Savara's poster presentation at CHEST 2024?
What is the title of Savara's accepted abstract for CHEST 2024?
When and where will Savara's Industry Symposium take place at CHEST 2024?
Who will be speaking at Savara's Industry Symposium at CHEST 2024?
